These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 6248279)

  • 1. Acute cytomegalovirus infection and the host immune response. I. Development and maintenance of cytomegalovirus (CMV) induced in vitro lymphocyte reactivity and its relationship to the production of CMV antibodies.
    ten Napel CH; The TH
    Clin Exp Immunol; 1980 Feb; 39(2):263-71. PubMed ID: 6248279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cellular immune response to cell-associated and cell-free cytomegalovirus (CMV) antigens after primary CMV-infection in non-immunocompromised hosts: development and maintenance of CMV-latency and its influence on immunocompetence.
    Roenhorst HW; Kallenberg CG; The TH
    Clin Exp Immunol; 1988 Dec; 74(3):326-32. PubMed ID: 2853014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute cytomegalovirus infection and the host immune response. II. Relationship of suppressed in vitro lymphocyte reactivity to bacterial recall antigens and mitogens with the development of cytomegalovirus-induced lymphocyte reactivity.
    ten Napel CH; The TH
    Clin Exp Immunol; 1980 Feb; 39(2):272-8. PubMed ID: 6248280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of cytomegalovirus infection on T lymphocytes after allogeneic bone marrow transplantation.
    Würsch AM; Gratama JW; Middeldorp JM; Nissen C; Gratwohl A; Speck B; Jansen J; D'Amaro J; The TH; De Gast GC
    Clin Exp Immunol; 1985 Nov; 62(2):278-87. PubMed ID: 3002684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintenance of cytomegalovirus (CMV) latency and host immune responses of long term renal allograft survivors. I. Prolonged suppression of in vitro lymphocyte responses against CMV infected fibroblasts related to previous secondary CMV infection.
    Roenhorst HW; Middeldorp JM; Beelen JM; Schirm J; Tegzess AM; The TH
    Clin Exp Immunol; 1985 Mar; 59(3):709-15. PubMed ID: 2985307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific immunity after congenital or neonatal infection with cytomegalovirus or herpes simplex virus.
    Hayward AR; Herberger MJ; Groothuis J; Levin MR
    J Immunol; 1984 Nov; 133(5):2469-73. PubMed ID: 6207230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of cytomegalovirus in the T cell changes seen in elderly individuals.
    Looney RJ; Falsey A; Campbell D; Torres A; Kolassa J; Brower C; McCann R; Menegus M; McCormick K; Frampton M; Hall W; Abraham GN
    Clin Immunol; 1999 Feb; 90(2):213-9. PubMed ID: 10080833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic effect of the acquisition of cytomegalovirus-specific immune response during preemptive treatment.
    Benmarzouk-Hidalgo OJ; Cisneros JM; Cordero E; Martín-Peña A; Sanchez B; Martin-Gandul C; Gentil MA; Gomez-Bravo MA; Lage E; Perez-Romero P
    Transplantation; 2011 Apr; 91(8):927-33. PubMed ID: 21358366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact on the cytomegalovirus (CMV) viral load by CMV-specific T-cell immunity in recipients of allogeneic stem cell transplantation.
    Avetisyan G; Larsson K; Aschan J; Nilsson C; Hassan M; Ljungman P
    Bone Marrow Transplant; 2006 Nov; 38(10):687-92. PubMed ID: 17001346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic utility of human cytomegalovirus-specific T-cell response monitoring in predicting viremia in pediatric allogeneic stem-cell transplant patients.
    Abate D; Cesaro S; Cofano S; Fiscon M; Saldan A; Varotto S; Mengoli C; Pillon M; Calore E; Biasolo MA; Cusinato R; Barzon L; Messina C; Carli M; Palù G
    Transplantation; 2012 Mar; 93(5):536-42. PubMed ID: 22314338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cytomegalovirus IgM amd IgG antibodies in the sera of patients with acute and chronic upper respiratory infections].
    Cengiz AT; Ataoğlu H; Kiyan M; Kiliç H
    Mikrobiyol Bul; 1990 Oct; 24(4):307-13. PubMed ID: 1962842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High levels of CMV-IE-1-specific memory T cells are associated with less alloimmunity and improved renal allograft function.
    Nickel P; Bold G; Presber F; Biti D; Babel N; Kreutzer S; Pratschke J; Schönemann C; Kern F; Volk HD; Reinke P
    Transpl Immunol; 2009 Mar; 20(4):238-42. PubMed ID: 19032982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological study of cytomegalovirus complement-fixing antibodies in the population of the CSR.
    Seeman J
    J Hyg Epidemiol Microbiol Immunol; 1976; 20(4):489-96. PubMed ID: 192796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytomegalovirus infection in transplant recipients resolves when circulating gammadelta T lymphocytes expand, suggesting a protective antiviral role.
    Lafarge X; Merville P; Cazin MC; Bergé F; Potaux L; Moreau JF; Déchanet-Merville J
    J Infect Dis; 2001 Sep; 184(5):533-41. PubMed ID: 11494158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 64,000 dalton matrix protein of human cytomegalovirus induces in vitro immune responses similar to those of whole viral antigen.
    Forman SJ; Zaia JA; Clark BR; Wright CL; Mills BJ; Pottathil R; Racklin BC; Gallagher MT; Welte K; Blume KG
    J Immunol; 1985 May; 134(5):3391-5. PubMed ID: 2580024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific cellular unreactivity during cytomegalovirus infection in man.
    Fiorilli M; Panà A; Sirianni MC; Spaziani A; Aiuti F
    Boll Ist Sieroter Milan; 1978 Sep; 57(4):452-7. PubMed ID: 216376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of cytomegalovirus carrier status on lymphocyte subsets and natural immunity.
    Gratama JW; Kardol M; Naipal AM; Slats J; Den Ouden A; Stijnen T; D'Amaro J; The TH; Bruning JW
    Clin Exp Immunol; 1987 Jul; 69(1):16-24. PubMed ID: 2820636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus-specific CD8+ T cells do not develop in all renal transplant patients at risk of virus infection.
    Christmas SE; Halliday D; Lawton N; Wang H; Abdalla I; Masters J; Hassan RL; Hart IJ; Khan N; Smith J; Hammad A; Bakran A
    Transpl Immunol; 2009 Dec; 22(1-2):99-104. PubMed ID: 19635559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients.
    Abate D; Saldan A; Fiscon M; Cofano S; Paciolla A; Furian L; Ekser B; Biasolo MA; Cusinato R; Mengoli C; Bonfante L; Rossi B; Rigotti P; Sgarabotto D; Barzon L; Palù G
    J Infect Dis; 2010 Aug; 202(4):585-94. PubMed ID: 20594105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintenance of cytomegalovirus (CMV) latency and host immune responses of long term renal allograft survivors. II. Secondary CMV infections associated with impaired in vitro proliferative responses to mitogens, allogeneic lymphocytes and CMV infected cells.
    Roenhorst HW; Beelen JM; Middeldorp JM; Schirm J; Tegzess AM; The TH
    Clin Exp Immunol; 1985 Jul; 61(1):72-9. PubMed ID: 2994923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.